Celularity IncNASDAQ:CELUNASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)
- LAST PRICE3.1900
- TODAY'S CHANGE (%)0.2400 (8.1356%)
- Bid / Lots2.9000/ 1
- Ask / Lots3.2700/ 1
- Open / Previous Close3.0000 / 2.9500
- Day Range
- 52 Week Range
- Volume36,900
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CELU |
|---|---|---|
| 09:32 ET | 1821 | 3 |
| 09:36 ET | 4967 | 3 |
| 09:41 ET | 100 | 3 |
| 10:06 ET | 2268 | 3 |
| 10:12 ET | 100 | 3.03 |
| 10:37 ET | 333 | 2.99 |
| 10:48 ET | 250 | 2.9948 |
| 10:51 ET | 200 | 2.975 |
| 10:55 ET | 100 | 3 |
| 10:57 ET | 100 | 3 |
| 11:00 ET | 100 | 3 |
| 11:02 ET | 375 | 3 |
| 11:04 ET | 382 | 3 |
| 11:06 ET | 1105 | 3 |
| 11:08 ET | 100 | 3 |
| 11:09 ET | 823 | 3 |
| 11:11 ET | 524 | 3 |
| 11:13 ET | 1102 | 3 |
| 11:15 ET | 455 | 3 |
| 11:24 ET | 366 | 3 |
| 01:26 ET | 2000 | 3 |
| 02:04 ET | 628 | 3 |
| 02:18 ET | 6752 | 3.04 |
| 02:29 ET | 952 | 3.04 |
| 02:31 ET | 200 | 3.1 |
| 02:45 ET | 500 | 3.23 |
| 02:51 ET | 3900 | 3.3 |
| 02:56 ET | 490 | 3.27 |
| 03:50 ET | 2217 | 3.115 |
| 03:56 ET | 400 | 3.19 |
| 03:57 ET | 119 | 3.19 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Celularity Inc | 64.3M | -0.3x | --- |
Turnstone Biologics Corp | 56.7M | -0.7x | --- |
Gritstone bio Inc | 70.6M | -0.4x | --- |
ImmuCell Corp | 33.6M | -8.4x | --- |
Carisma Therapeutics Inc | 49.9M | -0.6x | --- |
Aligos Therapeutics Inc | 40.6M | -0.3x | --- |
Company Information
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.
Contact Information
- Headquarters
- 170 Park AveFLORHAM PARK, NJ, United States 07932
- Phone
- 908-768-2170
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer
- Robert Hariri
- Chief Financial Officer
- David Beers
- President - Degenerative Disease
- Stephen Brigido
- Senior Executive Vice President, Chief Administrative Officer, General Manager
- John Haines
- Director
- Shiu Fei Ling
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $64.3M |
|---|---|
Revenue (TTM) | $14.8M |
Shares Outstanding | 21.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-10.51 |
Book Value | $13.36 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 4.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,272.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
